FBL7 Activators are a chemical class designed to interact specifically with the F-box/LRR-repeat protein 7 (FBL7), a member of the F-box protein family. F-box proteins are critical components of the ubiquitin-proteasome system, which is a fundamental pathway for protein degradation in eukaryotic cells. They function as specificity factors that recruit substrates to the SCF (SKP1-cullin 1-F-box protein) E3 ubiquitin ligase complex, thus tagging them for ubiquitination and subsequent proteolysis by the 26S proteasome. FBL7 Activators are molecules that bind to the FBL7 protein, influencing its activity. The exact mechanisms by which these activators exert their influence can vary, but generally involve modulating the protein-protein interactions that FBL7 engages in, or altering its structural conformation, which can affect its ability to bind to its partners within the SCF complex or its target substrates.
The biochemical pathways and cellular processes that involve FBL7 are diverse, owing to the ubiquity of protein degradation mechanisms in cellular regulation. By activating FBL7, these molecules can affect a variety of cellular functions, such as cell cycle progression, signal transduction, and gene expression, among others. The specific molecular design of FBL7 Activators allows them to have high selectivity for FBL7, which is advantageous for modulating the protein's activity with precision. Research into FBL7 and its interactions with other cellular components is ongoing, and the development of FBL7 Activators is part of a broader interest in understanding the role of F-box proteins in the regulation of proteostasis and cellular function. These activators are often used as tools in experimental settings to elucidate the biological roles of FBL7 and to study the molecular details of its function within the ubiquitin-proteasome pathway.
Items 11 to 17 of 17 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates S1P receptors, leading to diverse signaling cascades. If FBL7 operates downstream of S1P receptor signaling, S1P could enhance its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. If FBL7 is calcium-sensitive, thapsigargin could enhance its function. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore that increases intracellular calcium. Similar to ionomycin, if FBL7 functions are calcium-dependent, A23187 could enhance its activity. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid regulates gene expression and might influence GGPS1 as part of a broader effect on cellular growth and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. If FBL7 is regulated by p38 MAPK, inhibition by SB203580 could shift signaling in a way that enhances FBL7 activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. If FBL7 is part of signaling pathways that are regulated by tyrosine kinases, genistein could enhance FBL7's functional activity by reducing competitive tyrosine kinase signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor. If FBL7 activity is suppressed by a kinase that staurosporine inhibits, its activity could be enhanced through this inhibition. | ||||||